Levi & Korsinsky Investigates EyePoint Pharmaceuticals After LUCIA Trial Miss and 80% Share Drop

EyePoint Pharmaceuticals shares lost nearly 80% of their value after the company disclosed that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUCIA trial for wet age-related macular degeneration, and Levi & Korsinsky is now investigating potential securities law violations on behalf of shareholders who lost money, PR Newswire reported on October 19, 2026.

Levi & Korsinsky Opens EyePoint Investigation

The LUCIA Phase 3 trial's primary endpoint was statistical non-inferiority in mean change in best corrected visual acuity versus on-label 2 mg aflibercept control. DURAVYU failed to meet this endpoint, despite achieving key secondary endpoints, including a 38% reduction in treatment burden. EyePoint is a clinical-stage biopharmaceutical company developing sustained-release ophthalmic therapeutics using its Durasert E platform, with DURAVYU in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema, plus two FDA-approved commercial products, YUTIQ and DEXYCU.

Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money. The investigation concerns statements made before the LUCIA disclosure that allegedly caused investors to purchase securities at inflated prices. Investors who purchased EYPT stock or securities and suffered financial losses may be eligible, and eligibility is based on purchase date and documented losses, not on whether they still hold the shares. Joseph E. Levi, Esq. can be contacted by email or by telephone at (212) 363-7500.

Levi & Korsinsky has represented shareholders in securities class actions for over two decades and was ranked in the ISS Top 50 for seven consecutive years. On October 9, 2026, the firm notified stockholders of an investigation into the fairness of Priority Technology Holdings' acquisition by its largest stockholder, Thomas C. Priore, according to PR Newswire.

EyePoint's Trial Enrollment and Financing Record

According to akta.pro company records, EyePoint's Phase 3 LUGANO trial for DURAVYU in wet age-related macular degeneration was fully enrolled with over 900 patients as of August 2026, with topline data readout expected in August 2026. The company completed enrollment in both Phase 3 COMO and CAPRI trials for DURAVYU in diabetic macular edema with over 480 patients in July 2026, ahead of schedule. EyePoint recorded a $150 million stock offering in October 2025 that was oversubscribed to $172.5 million, and its total funding stands at $803.8 million.

Earlier EyePoint Coverage Before the Investigation

On October 19, 2026, TradingView reported that EyePoint's LUCIA Phase 3 topline showed DURAVYU did not meet non-inferiority for mean best corrected visual acuity versus on-label aflibercept, while key secondary endpoints were met, including a 38% reduction in treatment burden and 52% supplement-free at Week 56. On October 6, 2026, FinancialContent Business Page reported that Pomerantz LLP was investigating securities fraud claims on behalf of EyePoint investors after the company's stock fell 66.98% to $4.87 on August 17, 2026, following a failed Phase 3 trial for its wet age-related macular degeneration drug.

What Comes Next for EyePoint

EyePoint's Phase 3 LUGANO trial for DURAVYU in wet age-related macular degeneration has topline data readout expected in August 2026, according to akta.pro company records.